QiShenYiQi Pill Ameliorates Cardiac Fibrosis After Pressure Overload-Induced Cardiac Hypertrophy by Regulating FHL2 and the Macrophage RP S19/TGF-β1 Signaling Pathway

• Main Authors: Gulinigaer Anwaier (Author), Ting-Ting Xie (Author), Chun-Shui Pan (Author), An-Qing Li (Author), Li Yan (Author), Di Wang (Author), Fan-Kai Chen (Author), Ding-Zhou Weng (Author), Kai Sun (Author), Xin Chang (Author), Jing-Yu Fan (Author), Jing-Yan Han (Author), Jian Liu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Purpose: Heart failure (HF) is a leading cause of morbidity and mortality worldwide, and it is characterized by cardiac hypertrophy and fibrosis. However, effective treatments are not available to block cardiac fibrosis after cardiac hypertrophy. The QiShenYiQi pill (QSYQ) is an effective treatment...